JP5513741B2 - プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 - Google Patents

プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 Download PDF

Info

Publication number
JP5513741B2
JP5513741B2 JP2008513829A JP2008513829A JP5513741B2 JP 5513741 B2 JP5513741 B2 JP 5513741B2 JP 2008513829 A JP2008513829 A JP 2008513829A JP 2008513829 A JP2008513829 A JP 2008513829A JP 5513741 B2 JP5513741 B2 JP 5513741B2
Authority
JP
Japan
Prior art keywords
procaspase
pac
cells
caspase
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008513829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545718A (ja
JP2008545718A5 (OSRAM
Inventor
ポール， ジェイ． ハーゲンロザー，
カーソン， エス． パット，
グレイス， ダブリュー． チェン，
ジェニファー， エム． ペアソン，
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
Publication of JP2008545718A publication Critical patent/JP2008545718A/ja
Publication of JP2008545718A5 publication Critical patent/JP2008545718A5/ja
Application granted granted Critical
Publication of JP5513741B2 publication Critical patent/JP5513741B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2008513829A 2005-05-26 2006-05-26 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 Active JP5513741B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68480705P 2005-05-26 2005-05-26
US60/684,807 2005-05-26
US74387806P 2006-03-28 2006-03-28
US60/743,878 2006-03-28
US11/420,425 US20070049602A1 (en) 2005-05-26 2006-05-25 Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
US11/420,425 2006-05-25
PCT/US2006/020910 WO2006128173A2 (en) 2005-05-26 2006-05-26 Selective apoptotic induction in cancer cells including activation of procaspase-3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012251584A Division JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Publications (3)

Publication Number Publication Date
JP2008545718A JP2008545718A (ja) 2008-12-18
JP2008545718A5 JP2008545718A5 (OSRAM) 2009-07-16
JP5513741B2 true JP5513741B2 (ja) 2014-06-04

Family

ID=37452994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008513829A Active JP5513741B2 (ja) 2005-05-26 2006-05-26 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導
JP2012251584A Active JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012251584A Active JP5907852B2 (ja) 2005-05-26 2012-11-15 プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導

Country Status (10)

Country Link
US (1) US20070049602A1 (OSRAM)
EP (3) EP2659884A3 (OSRAM)
JP (2) JP5513741B2 (OSRAM)
AU (1) AU2006251978A1 (OSRAM)
CA (1) CA2610366A1 (OSRAM)
DK (1) DK1893210T3 (OSRAM)
ES (1) ES2763156T3 (OSRAM)
IL (1) IL187603A0 (OSRAM)
MX (1) MX2007014843A (OSRAM)
WO (1) WO2006128173A2 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
EP2393794B1 (en) 2009-02-09 2017-03-22 The Board of Trustees of the University of Illionis Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
WO2010102513A1 (zh) * 2009-03-11 2010-09-16 深圳市湘雅生物医药研究院 高哌嗪乙酰肼类衍生物及其制备方法和用途
CN101805338B (zh) * 2010-04-06 2014-10-15 沈阳药科大学 噁二唑基哌嗪衍生物及其用途
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
CA2865983C (en) * 2012-03-02 2021-10-19 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
EP3290035B1 (en) 2012-03-06 2019-05-15 The Board of Trustees of the University of Illinois Procaspase combination therapy for treating cancer
DK2822558T3 (da) 2012-03-06 2020-03-23 The Board Of Trustees Of The Univ Of Illionis Procaspase 3 aktivering ved hjælp af kombinations terapi
BR112015002357B1 (pt) * 2012-08-03 2022-03-15 The Board Of Trustees Of The University Of Illinois Compostos e composições ativadores de enzimas
CN105218399B (zh) 2014-05-30 2018-02-09 中国人民解放军军事医学科学院毒物药物研究所 一种取代乙酰肼类衍生物、其制备方法及用途
BR112017026140A2 (pt) 2015-06-05 2018-08-14 The Board Of Trustees Of The University Of Illinois método para inibir o crescimento ou a proliferação de células cancerígenas, método para induzir apoptose em célula cancerígena, método para tratar câncer, composição e seu uso
WO2017012113A1 (zh) * 2015-07-23 2017-01-26 王智民 化合物pac-1或其盐及包含它们的药物组合物
CN105085421B (zh) * 2015-07-24 2017-12-26 深圳市湘雅生物医药研究院 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法
EP3327007B1 (en) 2015-07-24 2020-06-03 Shenzhen Zhenxing Medical Technology Co., Ltd. Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN111491927A (zh) * 2017-11-17 2020-08-04 伊利诺伊大学董事会 通过降解双mek信号传导的癌症疗法
MX2021003490A (es) 2018-10-05 2021-06-18 Univ Illinois Terapia combinada para el tratamiento de melanoma uveal.
WO2025129066A1 (en) * 2023-12-15 2025-06-19 The Regents Of The University Of California Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760765B2 (en) * 1997-05-22 2003-05-22 Burnham Institute, The Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
JP2002522032A (ja) 1998-07-27 2002-07-23 ファルマシア・アンド・アップジョン・カンパニー プロカスパーゼ８の自己活性化方法
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
US20020115613A1 (en) * 2001-02-16 2002-08-22 Kumar M. Vijay Treatment of prostate cancer
KR100439425B1 (ko) * 2001-03-22 2004-07-05 (주)바이오케어 잔토리졸을 포함하는 조성물 및 그 용도
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
JP2006508666A (ja) * 2002-12-10 2006-03-16 オタワ ヘルス リサーチ インスティテュート カスパーゼ３活性調節による幹細胞分化の調節
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3

Also Published As

Publication number Publication date
EP1893210B1 (en) 2019-10-02
JP2008545718A (ja) 2008-12-18
CA2610366A1 (en) 2006-11-30
JP2013100285A (ja) 2013-05-23
AU2006251978A1 (en) 2006-11-30
EP2634581A1 (en) 2013-09-04
ES2763156T3 (es) 2020-05-27
WO2006128173A3 (en) 2007-05-24
IL187603A0 (en) 2008-03-20
MX2007014843A (es) 2008-02-14
DK1893210T3 (da) 2020-01-13
WO2006128173A2 (en) 2006-11-30
US20070049602A1 (en) 2007-03-01
EP2659884A3 (en) 2014-10-01
EP1893210A4 (en) 2010-09-01
EP1893210A2 (en) 2008-03-05
EP2659884A2 (en) 2013-11-06
JP5907852B2 (ja) 2016-04-26

Similar Documents

Publication Publication Date Title
JP5907852B2 (ja) プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導
US11612598B2 (en) Compounds and methods for the treatment of cancer
Yuan et al. Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy
Agarwal et al. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells
Smith et al. Synthetic analogs of green tea polyphenols as proteasome inhibitors
Hamdoun et al. Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity
US11584718B2 (en) Activators of the unfolded protein response
JP2015025021A (ja) 個別化された抗癌薬としてのプロカスパーゼ活性化化合物の設計、合成および評価
Hockenbery et al. Mitochondria and apoptosis: new therapeutic targets
Wang et al. Targeting procaspase‐3 with WF‐208, a novel PAC‐1 derivative, causes selective cancer cell apoptosis
Romagnoli et al. Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents
CN101184491A (zh) 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US20090163577A1 (en) METHODS AND COMPOSITIONS FOR ANTAGONIZING ANTI-APOPTOTIC Bcl-2-FAMILY PROTEINS
Wang et al. Novel thiohydantoin analogues bearing the 1-hydroxyl-2, 2, 2-trifluoro-1-ethyl moiety as androgen receptor inhibitors for the potential treatment of castration resistant prostate cancer
KR101400505B1 (ko) Ｐ５３ 기능을 대체하거나 작동시키는 소형 분자
CN116768919B (zh) 取代氨基苯基呋喃并吡啶化合物及其制备方法、药物组合物和应用
Song et al. Discovery of SA-8 as a Potent SHP2-AUTAC Degrader in Cancer Therapy
US20250114313A1 (en) Oligo-benzamide analogs and their use in cancer treatment
JP2012102087A (ja) タンパク質リシンメチル化酵素Ｓｅｔ７／９の阻害物質を含有する疾患の予防・治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130515

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140328

R150 Certificate of patent or registration of utility model

Ref document number: 5513741

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250